Although CAR-T therapy has demonstrated significant efficacy in clinical trials for specific solid tumors (such as CEA-targeted colorectal cancer and GPC3-targeted hepatocellular carcinoma), its efficacy is inherently limited by the biological background of the tumor. The gene discussed is GPC3; the disease is hepatocellular carcinoma.